Over the last few years, we’ve been battling an array of organic malware attacks from various SARS-CoV-2 variants that have been exploiting a zero-day vulnerability (CVE-2019-05309) in host system immunity. Fortunately, prominent pharma security vendors, such as Pfizer, have made the required software patches available to thwart these attacks using the latest mRNA host cell programming technology.
Some host system operators have been reluctant to deploy the new patches, citing dubious and unsupportable claims of insufficient beta testing, an accelerated development cycle, and potential unknown system-wide effects.
Regardless, the first three versions of the Pfizer Booster have been remarkably effective in keeping hundreds of millions of potentially affected systems from undergoing emergency intervention or worse — decommissioning.
We recently had the opportunity to put Pfizer’s latest software patch, version 4, to the test, after interfacing with a pair of patched but infected systems at a local hibachi restaurant a week ago last Sunday.
Here’s how we did.
Easy Install Reduces Severity of Infection Reduces Downtime Prevents Emergency Intervention Prevents System Decommissioning
Short-Term Malware Infection Simulation Potential Shortage of Reviewable Entertainment Material